Use of dupilimab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis

Elaine C. Siegfried*, Sean Igelman, Jennifer C. Jaworsk, Richard J. Antaya, Kelly M. Cordoro, Lawrence F. Eichenfield, Moise L. Levy, Amy S. Paller

*Corresponding author for this work

Research output: Contribution to journalComment/debate

9 Scopus citations
Original languageEnglish (US)
Pages (from-to)172-176
Number of pages5
JournalPediatric dermatology
Volume36
Issue number1
DOIs
StatePublished - Jan 1 2019

Keywords

  • adverse effects
  • atopic dermatitis
  • biologic
  • dupilumab
  • pediatric drug use

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Dermatology

Cite this

Siegfried, E. C., Igelman, S., Jaworsk, J. C., Antaya, R. J., Cordoro, K. M., Eichenfield, L. F., Levy, M. L., & Paller, A. S. (2019). Use of dupilimab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis. Pediatric dermatology, 36(1), 172-176. https://doi.org/10.1111/pde.13707